413 related articles for article (PubMed ID: 2411125)
1. Evaluation of serum pancreatic enzymes, carbohydrate antigen 19-9, and carcinoembryonic antigen in various pancreatic diseases.
Satake K; Kanazawa G; Kho I; Chung Y; Umeyama K
Am J Gastroenterol; 1985 Aug; 80(8):630-6. PubMed ID: 2411125
[TBL] [Abstract][Full Text] [Related]
2. [Assay of serum elastase 1 in adenocarcinoma of the pancreas: diagnostic value, compared and combined study with serum CEA and CA 19-9].
Charneau J; Douay O; Daver A; Boyer J
Gastroenterol Clin Biol; 1988; 12(6-7):548-52. PubMed ID: 3166429
[TBL] [Abstract][Full Text] [Related]
3. Estimation of carbohydrate antigen (CA) 19-9 levels in pure pancreatic juice of patients with pancreatic cancer.
Nishida K; Tasaki N; Miyagawa H; Yoshikawa T; Kondo M
Am J Gastroenterol; 1988 Feb; 83(2):126-9. PubMed ID: 3422536
[TBL] [Abstract][Full Text] [Related]
4. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
Ozkan H; Kaya M; Cengiz A
Hepatogastroenterology; 2003; 50(53):1669-74. PubMed ID: 14571813
[TBL] [Abstract][Full Text] [Related]
5. Carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA) in pancreatic cancer. Role of age and liver dysfunction.
Del Favero G; Fabris C; Panucci A; Basso D; Plebani M; Baccaglini U; Leandro G; Burlina A; Naccarato R
Bull Cancer; 1986; 73(3):251-5. PubMed ID: 3530354
[TBL] [Abstract][Full Text] [Related]
6. Serum CA 242 in pancreatic cancer. Comparison with CA 19-9 and CEA.
Pezzilli R; Billi P; Plate L; Laudadio MA; Sprovieri G
Ital J Gastroenterol; 1995; 27(6):296-9. PubMed ID: 8562994
[TBL] [Abstract][Full Text] [Related]
7. Multiparametric tumor marker (CA 19-9, CEA, AFP, POA) analyses of pancreatic juices and sera in pancreatic diseases.
Schmiegel WH; Eberl W; Kreiker C; Kalthoff H; Bützow GH; Jessen K; Klapdor R; Soehendra N; Wargenau M; Classen M
Hepatogastroenterology; 1985 Jun; 32(3):141-5. PubMed ID: 2410346
[TBL] [Abstract][Full Text] [Related]
8. [Diagnostic usefulness and limitation of measuring pancreatic cancer associate antigen, SPan-1, in patients with pancreatic cancer].
Satake K; Chung YS; Umeyama K; Takeuchi T; Kim YS
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1139-46. PubMed ID: 2730018
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical staining of pancreatic cancer with CA19-9, KM01, unabsorbed CEA, and absorbed CEA. A comparison with normal pancreas and chronic pancreatitis.
Shimizu M; Saitoh Y; Ohyanagi H; Itoh H
Arch Pathol Lab Med; 1990 Feb; 114(2):195-200. PubMed ID: 1689141
[TBL] [Abstract][Full Text] [Related]
10. [Serum pancreatic enzymes and enzyme inhibitor as a tumor marker for pancreatic cancer].
Ogawa M
Rinsho Byori; 1986 Nov; 34(11):1229-35. PubMed ID: 2434691
[No Abstract] [Full Text] [Related]
11. [The role of CEA, CA 19-9 and TPA in the diagnosis of pancreatic cancer. Evaluation by discriminant analysis].
Basso D; Fabris C; Del Favero G; Panucci A; Piccoli A; Plebani M; Pedrazzoli S; Baccaglini U; Lise M; Burlina A
Minerva Med; 1986 Apr; 77(16):613-6. PubMed ID: 3458035
[TBL] [Abstract][Full Text] [Related]
12. CA 19-9 assay in differential diagnosis of pancreatic carcinoma from inflammatory pancreatic diseases.
Piantino P; Andriulli A; Gindro T; Pecchio F; Masoero G; Cavallini G; Naccarato R; Dobrilla G
Am J Gastroenterol; 1986 Jun; 81(6):436-9. PubMed ID: 3458359
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of combined use of CEA, CA19-9 and CA50 in the serum of patients with pancreatic carcinoma.
Lucarotti ME; Habib NA; Kelly SB; Rothnie ND; Nelson O; Lindholm L; Cooper MJ; Wood CB; Williamson RC
Eur J Surg Oncol; 1991 Feb; 17(1):51-3. PubMed ID: 1995358
[TBL] [Abstract][Full Text] [Related]
14. [Diagnostic importance of the tumor marker CA 19-9 in pancreatic cancer].
Safi F; Büchler M; Schenkluhn B; Beger HG
Dtsch Med Wochenschr; 1984 Dec; 109(49):1869-73. PubMed ID: 6209082
[TBL] [Abstract][Full Text] [Related]
15. [CA 12-5 in cancer of the digestive tract. A comparison with CA 19-9 and CEA in cancer of the pancreas and colon].
Klapdor R; Klapdor U; Bahlo M; Dallek M; Kremer B; van Ackeren H; Schreiber HW; Greten H
Dtsch Med Wochenschr; 1984 Dec; 109(51-52):1949-54. PubMed ID: 6595110
[TBL] [Abstract][Full Text] [Related]
16. Clinical evaluation of tissue polypeptide antigen (TPA) in the diagnosis of pancreatic carcinoma.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttila I
Anticancer Res; 1993; 13(5C):1883-7. PubMed ID: 8267397
[TBL] [Abstract][Full Text] [Related]
17. Comparative studies of DU-PAN-2, carcinoembryonic antigen, and CA19-9 in the serum and bile of patients with pancreatic and biliary tract diseases: evaluation of the influence of obstructive jaundice.
Ohshio G; Manabe T; Watanabe Y; Endo K; Kudo H; Suzuki T; Tobe T
Am J Gastroenterol; 1990 Oct; 85(10):1370-6. PubMed ID: 2220731
[TBL] [Abstract][Full Text] [Related]
18. [Comparative study of the role of CA 19-9, CA 72-4 and CEA tumor antigens in the diagnosis of pancreatic cancer and other gastrointestinal malignant diseases].
Czakó L; Takács T; Babarczy E; Dux L; Lonovics J
Orv Hetil; 1997 Nov; 138(47):2981-5. PubMed ID: 9432648
[TBL] [Abstract][Full Text] [Related]
19. Immunological diagnosis of pancreatic cancer by assaying carcinoembryonic antigen (CEA) in pure pancreatic juice.
Nishida K; Yoshikawa T; Kondo M; Thiele HG
Hepatogastroenterology; 1980 Dec; 27(6):488-94. PubMed ID: 7203382
[TBL] [Abstract][Full Text] [Related]
20. [Tumor markers of pancreatic cancer].
Takami H; Hishinuma S; Shintoku J; Furuuchi T; Ogata Y; Abe O
Gan To Kagaku Ryoho; 1985 Feb; 12(2):212-9. PubMed ID: 3855615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
